Research collaboration to identify the remaining enzymes and transcription factors responsible for converting bitter, toxic steroidal glycoalkaloids into edible esculeosides during tomato fruit ripening, using co-expression analysis of RNA sequencing data across developmental stages.
This research addresses a key question in tomato fruit biology and food safety: how toxic, bitter steroidal glycoalkaloids (SGAs) are naturally converted into edible esculeosides during tomato ripening. While cultivated tomatoes are safe to eat, wild relatives and some breeding lines accumulate harmful SGAs. Only one gene in this conversion pathway (the C-23 hydroxylase GAME31) has been identified to date. The remaining enzymes that perform sterol acetylation, hydroxylation, and glycosylation, along with the transcription factors that regulate them, remain unknown. This project seeks to identify these missing genes, enabling future applications in tomato breeding, food safety, and metabolic engineering.
Research approach:
Scientific rationale: Genes involved in related specialized metabolic pathways in tomato co-express because they are activated by shared transcription factors, such as the known regulator GAME9. Therefore, genes involved in the SGA-to-esculeoside conversion should display similar co-expression patterns, making transcriptomics a powerful discovery tool.
This is an early-stage fundamental research project (TRL 1–2). The first gene in the pathway (GAME31) has been identified, but the remaining enzymes and transcription factors are not yet characterized. The proposed RNA sequencing, co-expression analysis, and homology-based candidate prioritization represent the discovery and validation phases. Functional characterization of candidate genes would constitute the next stage of development toward potential applications in crop improvement and food safety.
Virginia Polytechnic Institute and State University (Virginia Tech) is a comprehensive public land‑grant research university with broad graduate and professional programs and a strong industry orientation. An adjacent research and technology park links companies with faculty, shared labs, and prototyping resources, while facilities in the National Capital Region create a direct connection to federal partners and supply‑chain collaborators. Integration with a regional health system supports clinical research and translational pathways, and the statewide extension network enables field deployment and validation with industry and communities. Research is supported by competitive federal funding from agencies such as NSF, NIH, DOE, USDA, and the Department of Defense. A dedicated technology transfer office provides IP management, licensing, startup formation, and industry contracting support.